Funding dependence is the central issue

Adherium Limited (ASX:ADR) sells digital respiratory-health tools, and its latest filings show a company growing Recurring Revenue while leaning on short-term loans from a major Shareholder to fund operations. That combination is the main thing for readers of the health technology sector to understand about the stock.

What the company does

Adherium is based in Melbourne and describes itself as a provider of digital respiratory management. Its product is the US FDA-cleared Hailie Smartinhaler platform, which lets clinicians and patients remotely monitor inhaler use and adherence. The company states that it has sold more than 180,000 connected respiratory devices globally. Its commercial focus is remote patient monitoring (RPM) in the United States.

Latest quarter: growth in subscriptions

In its Appendix 4C for the quarter ended 30 June 2026, released on 29 July 2026, Adherium reported RPM subscription revenue of A$479,000 accrued, up 39% from A$344,000 in the prior quarter. The company noted that the figure excludes device sales.

Adherium reported 1,684 device shipments in the quarter, taking the cumulative total to 5,302, and set a target of about 10,000 shipments by 31 December 2026. That target is company guidance, not a result.

The company highlighted preliminary interim results from an Intermountain Health study presented at the American Thoracic Society conference in May 2026, which it said showed a fall of about 57% in total cost of care per patient per year and a 50% reduction in hospital admissions. These are interim and preliminary findings reported by the company, not regulatory approvals or final trial outcomes.

Cash, burn and borrowing

Cash at 30 June 2026 was about A$1.38 million, down from A$2.96 million at 31 March 2026. Operating cash outflow was A$3.91 million in the quarter and A$14.88 million over twelve months. The Appendix 4C itself estimated only 0.35 quarters of funding at the quarterly burn rate. Management said it was confident of raising sufficient funds, which had not been secured at the time.

Financing inflow was A$2.37 million in the quarter, largely from loans provided by Trudell Medical Limited, a major shareholder. A A$2.40 million Loan was drawn in June at 12% interest. The company reported A$2.69 million of facilities drawn and no undrawn facilities at quarter end.

Further borrowing followed. On 18 August 2026 Adherium announced a A$1 million unsecured short-term Facility from Trudell at 12% a year, capitalised monthly, due 30 September 2026 unless extended month to month. On 7 October 2026 it announced a A$700,000 Unsecured Loan from Barvest Ventures, a related entity, also at 12%, with repayment due 30 September 2027. The board said third-party funding was limited, uncertain or less favourable, and that the loans do not dilute shareholders. Director George Baran, who is associated with Trudell, abstained.

Risks and sector context

The key company-specific risk is liquidity. Borrowing at 12% adds interest costs, and the loans must be repaid or refinanced, while quarterly outflows have far exceeded customer receipts. Reliance on related-party lenders is another point to watch.

Sector conditions are mixed. The company points to new 2026 US reimbursement codes that cut the data-collection threshold from 15 days to two, which it expects to widen its addressable market. That is the company's expectation and depends on adoption by providers and payers.